Acute lymphoblastic leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology Guidelines
| Authors: | Shah, B.; Mattison, R. J.; Abboud, R.; Abdelmessieh, P.; Aldoss, I.; Burke, P. W.; DeAngelo, D. J.; Dinner, S.; Fathi, A. T.; Gauthier, J.; Haddadin, M.; Jain, N.; Jonas, B.; Kirby, S.; Liedtke, M.; Litzow, M.; Logan, A.; Long, M. X.; Luger, S.; Mangan, J. K.; Massaro, S.; May, W.; Oluwole, O.; Park, J.; Przespolewski, A.; Rangaraju, S.; Saygin, C.; Schwartz, M.; Shami, P.; Tomlinson, B.; Webster, J.; Awotiwon, A.; Stehman, K. |
| Title: | Acute lymphoblastic leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology |
| Abstract: | The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence. |
| Keywords: | cyclophosphamide; minimal residual disease; remission; induction therapy; stem-cell transplantation; prognostic-significance; term-follow-up; inotuzumab ozogamicin; hyperfractionated; adult patients; philadelphia-chromosome; 1st complete |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 22 |
| Issue: | 8 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2024-10-01 |
| Start Page: | 563 |
| End Page: | 576 |
| Language: | English |
| ACCESSION: | WOS:001415695700014 |
| DOI: | 10.6004/jnccn.2024.0051 |
| PROVIDER: | wos |
| PUBMED: | 39413812 |
| Notes: | Source: Wos |
